Flagellin FliC VacciGrade™

Recombinant flagellin from S. typhimurium

Bacterial flagellin, a TLR5 ligand, is a potent T-cell antigen and has potential as a vaccine adjuvant. Unlike other TLR agonists, flagellin tends to produce mixed Th1 and Th2 responses rather than strongly Th1 responses.

Flagellin Flic VacciGrade™ is suitable for preclinical studies. It is prepared under strict aseptic conditions. It is guaranteed sterile and thoroughly tested for the presence of endotoxins.

This product is for research use only, not for use in humans.

Specifications

Specificity: Th1/Th2 response

Working concentration: 1 -10 μg/mouse

Solubility: 500 µg/ml in physiological water

Quality control :

• Guaranteed sterile
• Endotoxin level: <0.005  EU/μg  (measurement  by  kinetic  chromogenic  LAL  assay)

Contents

• 50 µg of sterile lyophilized Flagellin FliC VacciGrade™
• 10 ml sterile endotoxin-free physiological water (NaCl 0.9%)

Shipped at room temperature.

This product should be stored at -20°C.

Lyophilized product is stable 1 year at -20°C when properly stored.

Details

Flagellin FliC is a recombinant flagellin protein encoded by the fliC gene from Salmonella typhimurium. Bacterial flagellin, a TLR5 ligand, is a potent T-cell antigen and has potential as a vaccine adjuvant.

Unlike other TLR agonists, flagellin tends to produce mixed Th1 and Th2 responses rather than strong Th1 responses [1].

It has been demonstrated that flagellin can act as a potent adjuvant in flu vaccines [2, 3].

Furthermore, flagellin can also signal through the NLRC4 inflammasome [4], although it is not known whether this pathway contributes to the adjuvant activity of flagellin.

1. Huleatt J. et al., 2007. Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine 25(4): 763-75.
2. Mbow ML. et al., 2010. New adjuvants for human vaccines. Curr Opin Immunol. 22(3):411-6.
3. Skountzou I. et al., 2010. Salmonella flagellins are potent adjuvants for intranasally administered whole inactivated influenza vaccine. Vaccine 28(4): 4103-12.
4. Miao EA. & Warren SE., 2010. Innate immune detection of bacterial virulence factors via the NLRC4 inflammasome. J Clin Immunol. 30(4): 502-6